MannKind Corporation to Present at the J.P. Morgan 2016

[yash]

VALENCIA, Calif., Dec. 29, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) (MNKD), focused on the discovery and development of therapeutic products for diabetes, announced today that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016 at 3:30 PM (PST) at Westin St. Francis Hotel in San Francisco, California.

Presenting from the Company will be its Chief Executive Officer, Duane DeSisto and Chief Financial Officer, Matthew Pfeffer.


finance.yahoo.com/news/mannkind-corporation-present-j-p-140000773.html

[Deleted]

This conference should put an end to the Sanofi partnership split. Hopefully, additional good information will be provided.

[LosingMyBullishness]

Let's see if Olsen is around and how DDS deals with him. I hope that this creates enough angst at the shorts to move up the options for the Jan 15 calls. They are pretty cheap right now.

[cjc04]

Who writes the press release for these announcements? Since when is MNKD focused on just diabetes?


"VALENCIA, Calif., Dec. 29, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) (MNKD), focused on the discovery and development of therapeutic products for diabetes'"

[mnholdem]

I noticed that myself. The wording is slightly different in the "About" section (below) than it is in the body of the PR, but I wouldn't read anything into it.

About MannKind Corporation

MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Company Contact:
Matthew J. Pfeffer
Corporate Vice President and
Chief Financial Officer
[phone]
[e-mail]

 - See more at: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=948255#sthash.jcxRri8p.dpuf

[cretin11]

Dec 29, 2015 9:54:26 GMT -5 LosingMyBullishness said:

Let's see if Olsen is around and how DDS deals with him. I hope that this creates enough angst at the shorts to move up the options for the Jan 15 calls. They are pretty cheap right now.

Why would you expect much movement on the Jan 15 calls, and at what strike price(s) are you hoping to see movement?

[LosingMyBullishness]

hi Cretin,
at the money call with a strike at 1.5. Premium is 0.17. Probability 31% without an event.

He conference will be on the 12th. One could expect that the new CEO will talk about a new TS application or a change in MNKD's strategy( I doubt that SNY would opt out as they have right now the perfect control).
This creates uncertainty at the short that have right now more at risk than the longs. There is still a lot of shorts to be covered and a lot of negative outlook baked into the price of the stock. On the otherhand it is less likely that they can short the company to death. Otherwise DDS would not have decided to join as CEO. He surely look at MNKD in detail and he knows where to look for value.
There was yesterday or so another typical bashing article at SA, a good sign for nervousness of shorts.

So 31% prob without a atypical move from the shorts but rather likely that they increase covering.

Discl.: Please keep in mind that I am intrinsic bullish and that this is not a financial advice. I am deep in red waters both in shares and options.

[cretin11]

intrinsic, thanks for sharing that rationale. To me it seems like such a long shot that buying those calls would pay off, and too likely to be throwing money away. Seems like whenever we have conf calls the bashers succeed in plunging the share price. Hoping the new boss will reverse that trend, maybe even some real news as a catalyst. To say we're overdue is understatement. But I'm more of a selling-puts type than buying-calls. As a result I have way more shares now than ever dreamed, so it hasn't worked well but hopefully long term it will. (And I have sold some of those same $1.50 puts for Jan 15, wondering if I'll get called in.)

[LosingMyBullishness]

Dec 31, 2015 17:21:57 GMT -5 cretin11 said:

intrinsic, thanks for sharing that rationale. To me it seems like such a long shot that buying those calls would pay off, and too likely to be throwing money away. Seems like whenever we have conf calls the bashers succeed in plunging the share price. Hoping the new boss will reverse that trend, maybe even some real news as a catalyst. To say we're overdue is understatement. But I'm more of a selling-puts type than buying-calls. As a result I have way more shares now than ever dreamed, so it hasn't worked well but hopefully long term it will. (And I have sold some of those same $1.50 puts for Jan 15, wondering if I'll get called in.)

Interesting. thanks for sharing your strategy. Never thought about selling puts. Guess you need a significant liquidity buffer to buy the stock below strike price and sell it when the price Incl premium is positive?

[cretin11]

That's right (about the buffer). Suffice it to say, I have needed that buffer with MNKD, having been selling puts since Afrezza got approval so you can imagine it's not pretty how far down I am in some of them. Basically every put you sell you should assume you'll get called in, and the premium effectively lowers your share price. Only sell puts on stock you want to own, don't do it for the fat premium of course.

But one of these days (hopefully), the buying calls strategy will be the right play. I've just given up trying to guess that timing.

[kball]

Back to the JP Morgan conference...

I've opined privately to a couple folks on this board that perhaps all Mannkind presents at this conference is the data they collected and evaluated last month in SD from Sam, Eric and the other 10 early adopters.

I'd like more and will happily take more announcements, but every optimistic thought i've entertained with this company (other than how remarkable the drug is) has been crushed along with the share price and the value of my investment account. That 4th quarter upon reflection was absolutely brutal...enough to turn many longtime posters on this board very negative and quite a few to sell out their entire position or a majority of it.

[EveningOfTheDay]

Unfortunately you are completely right, the fourth quarter was brutal and a serious eye opener into the reality of our situation. I do hope that we will get good news, but do not expect things to change much until RX pick up considerably. If Minnkind holds an ace in its sleeve now would be a good time to use it, at least in terms of letting us know they have a viable plan to their current situation that does not contemplate massive dilution.
Obviously as a general principle I will be delighted that Afrezza survives regardless of how it does it. I believe that with enough time many diabetics could benefit from using it to achieve very close to normal lives. However, as an investor interested in making money I remain extremely concerned that any money I still have is at considerable risk and/or that any substantial return on investment will take still years for me to see.

[mnholdem]

IMO, any of these announcements at the JP Morgan conference could have a significant impact on Wall Street sentiment for investing in MNKD stock;

Announcement of TS collaboration agreement(s) and substantial upfront payment(s);
Announcement of publication of a peer review based on patient data Sanofi has been gathering for nearly a year which shows Afrezza clearly demonstrated significant benefits for PWD, coupled with announcement of talks with FDA for label improvement based on same data plus data from clamp studies completed in 2015;
Announcement of plan for restructuring MannKind Corporation into two corporate entities, separating production capabilities (i.e. Afrezza) from pharmaceutical development.
Announcement of applications for marketing outside the U.S. 

[EveningOfTheDay]

I agree with you, it continues to be easy to speculate on relatively simple news that could represent a change of direction for the sp. However, at this point these are just speculation. The reality continues to be that other than in the science, us longs have been wrong over and over in the assessment of how the sp would respond to the situation. Yes, this could be simply blamed in an over optimistic view of the situation, but regardless of the reasons we have been wrong. I still read, from time to time, posts wishing an admission of being wrong from the likes of AF, JIM C or David K, but I cannot but to think they must be laughing at the thought. I do not doubt some degree of faul play in the form of manipulation, but if one has to be honest, one is forced to admit that it would have been much more profitable, or at least sensible to either short the stock or wait till the shorts were done with their play before buying long. Oh well, let's hope something good is coming our way. It would be nice to have a bone thrown to us to keep the faith alive.

[mnholdem]

I think that it's relevant that Duane mentioned improving shareholder value in his very first public statement after being hired. When I do my DD on other biotech/pharmaceutical development companies, they're issuing press releases that highlight positive test results from even preclinical studies. MannKind does none of that, so how are they suppose to attract BP or investors?

Hopefully, Duane DeSisto will see to it that the public gets a look at much more than blithe statements like, "we have a plethora of riches". Years ago, MannKind published test results for multiple API and Alfred Mann, and other leaders from within the company, openly talked about the various API they want to develop. But for the past several years, MannKind has gone silent. It may have an over reaction by Mann to the shareholder lawsuit, but the time has come for MannKind Corporation to become more vocal about their technology and potential. I hope DeSisto puts an immediate end to all the silence.